interaction records 54 assistance programs 55 0 personal data stored

Copay help by condition · Neurological and neuromuscular · read 2026-11-08

Stroke: which charitable copay funds are open

The one fund we hold for Stroke is closed or at capacity right now (read 2026-11-08).

Funds fill and reopen. Use the alert below, ask the manufacturer's program for your drug (see the assistance finder), and check your state's Medicaid coverage.

If you have Medicare Part D: CMS prints the annual out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026) (Table V-2 of its CY 2027 announcement). It is a benefit parameter and applies to covered drugs under plan rules. What changes on January 1.

Funds by status: 1 closed or at capacity1 closed

Swipe to read across

Funds we hold for Stroke, by the status each page gave on the day we read it.
What this is not. A record of what fund pages and FDA labels say, not advice and not a check of whether you qualify. US funds only. This page covers charitable funds from the organizations we read, the costs around a condition those funds pay for, and the drugs whose FDA label names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you.

A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.

Every fund we hold for Stroke

  • Closed or at capacityStroke

    TotalAssist (Patient Advocate Foundation copay funds) ·

    Award level: $1,500Insurance supported: Medicaid, Medicare, TRICARE

    The page lists the fund as Closed. Source page

Drugs whose FDA label names Stroke

6 drugs. Each row quotes the sentence of the drug's FDA label (Indications and Usage, openFDA) that names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you. Dashes in quotes are shown as hyphens. Of these, 3 have a program (in our assistance finder or on the program's own page) and 2 have a Medicare negotiated price in the CMS file; an empty cell says we found nothing in our data, not that nothing exists.

DrugWhat the FDA label saysManufacturer programMedicare negotiated price
Eliquis
Apixaban
Every route for this drug
... to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
A sentence about reducing the risk of this condition. Label on openFDA, read 2026-11-10
Eliquis 360 Support (via BMS/Pfizer)
BMS Access Support
Pfizer RxPathways Limited
and 2 more
$237.25 for a 30-day supply, effective 2027-01-01
Xarelto
Rivaroxaban
Every route for this drug
... to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.
A sentence about reducing the risk of this condition. Label on openFDA, read 2026-11-10
Xarelto Savings (via Janssen/J&J)
Heart Medication Assistance (Multiple Programs)
J&J Patient Assistance Foundation (JJPAF)
$202.33 for a 30-day supply, effective 2027-01-01
Brilinta
Ticagrelor
Every route for this drug
Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical ...
Label on openFDA, read 2026-11-10
Heart Medication Assistance (Multiple Programs)not in the CMS negotiated-price file
Pradaxa
Dabigatran Etexilate Mesylate
To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.
A sentence about reducing the risk of this condition. Label on openFDA, read 2026-11-10
not in our assistance findernot in the CMS negotiated-price file
Vascepa
Icosapent Ethyl
... as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and ...
A sentence about reducing the risk of this condition. Label on openFDA, read 2026-11-10
not in our assistance findernot in the CMS negotiated-price file
Simvastatin
Simvastatin
... the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease ...
A sentence about reducing the risk of this condition. Label on openFDA, read 2026-11-10
not in our assistance findernot in the CMS negotiated-price file

No broader or more specific condition page for this one.

Group: Neurological and neuromuscular. All conditions: the condition index. Fund board for every condition: charitable copay fund status.

What changed

First read on 2026-11-08. We keep each read with its date, so a fund reopening or closing will show here as a change. Until we have a second read there is nothing to compare, and we do not guess. The read date of every source is on the changes page.

This page as data

The same facts as JSON, each fund with its source URL and read date: stroke.json. Edition 2026-11, root 006ab9a329709cbe. See the licence page.

Questions

Is there an open charitable copay fund for Stroke?

As read on 2026-11-08, none of the 1 funds we hold for Stroke say they are open. Funds reopen, so use the alert on this page.

Which organizations run funds for Stroke?

TotalAssist (Patient Advocate Foundation copay funds). Each fund row on this page links to the organization's own page.

Does an open fund mean I qualify?

No. A status says whether a fund is taking applications. Eligibility, award level and which insurance it supports are each fund's own rules; where the page states them they are shown on the fund.

How current is this page?

Statuses are what each fund's own page said on the date we read it (2026-11-08). We do not promise a fund is still in that state today.